Why Conflicting Candidates Require a Decision
A first-in-human starting-dose assessment may produce several different candidate doses. A NOAEL-based calculation can point to one dose, an HNSTD-based calculation to another, and a MABEL or exposure-matching analysis to a third. Their disagreement is not automatically evidence that one calculation is wrong: each approach uses different evidence and addresses different uncertainties. The task is to decide which candidates are applicable, how much weight their evidence deserves, and what dose is defensible for the intended first exposure.
A candidate dose is an estimate for decision-making, not proof that the dose will be safe in humans. In particular, a lower number is not necessarily a better-supported number. A low estimate may be driven by a relevant and credible hazard, or it may depend on an inappropriate species, endpoint, or assumption. Conversely, a higher estimate may be supported by strong evidence, or may fail to account for a plausible human-specific risk.
Make the Candidates Comparable Before Ranking Them
Before interpreting a difference between candidates, verify that they refer to the same practical dose. A dose in mg/kg is not directly comparable with a total dose in mg unless body weight and the conversion are specified. Also check that candidates refer to the same route, formulation, dosing schedule, and population. A single-dose candidate should not be treated as equivalent to a repeated-dose candidate without considering how the intended regimen changes exposure.
Exposure-matching candidates require a further check: identify which exposure measure is being matched. A dose intended to keep human \(C_{\max}\) below a specified value does not necessarily keep AUC below its corresponding value. If both measures matter, retain both constraints and establish which is relevant to the anticipated hazard. Do not compare a dose based on one exposure metric with a dose based on another as if they had identical meanings.
The approaches also differ in what they contribute. A NOAEL-based candidate begins with a no-observed-adverse-effect level in an animal study and uses the applicable conversion and safety factor. An HNSTD-based candidate begins with the highest non-severely toxic dose, used in settings where that endpoint is appropriate. A MABEL-based candidate estimates a dose expected to produce a minimum anticipated biological effect, using relevant pharmacology and its translation to humans. An exposure-matching candidate uses a specified exposure limit or reference exposure to derive a human dose. These are not interchangeable endpoints; their value depends on the evidence behind them and on the risk the initial dose is intended to control.
A Structured Selection Rule
Treat each applicable candidate as a potential constraint on the initial dose, rather than as a vote in a numerical average. If every candidate is a credible upper bound for the same decision and all are expressed on a comparable basis, a conservative starting point is the smallest of those candidates. This rule only applies after the candidates have passed an applicability check. A candidate based on a misleading or irrelevant input should not become binding merely because it is numerically smallest.
Here \(D_i\) denotes a candidate that is being used as an upper constraint, not just any number produced during analysis. If all such constraints are applicable, the largest dose satisfying them is their minimum. The selected dose may be lower for a justified operational reason, such as a material uncertainty or a suitable available dose strength; it should not be rounded upward across a credible constraint. If a candidate is excluded from the set, the reason must be explicit and supported by the evidence.
This is a decision rule, not a theorem that the minimum candidate is safe. It assumes the candidates have been correctly calculated, are comparable, and represent relevant risks for the proposed first exposure. It also assumes that their stated limits have not been mistaken for precise biological thresholds. When a method produces an estimate rather than a hard limit, its uncertainty and evidential role must be considered before using it as a constraint.
Check units, body-weight basis, route, formulation, schedule, and the exposure metric behind each candidate. Resolve conversion errors before interpreting the disagreement.
Ask whether the source species, pharmacology, endpoint, and study conditions are relevant to the intended human exposure. Identify candidates that do not answer a meaningful question for this product.
Examine how directly the evidence supports the candidate, whether key measurements and assumptions are credible, and whether another independent approach corroborates or challenges it.
Use the most protective applicable constraints, explain any excluded candidate, and verify that the selected dose is feasible and has not been increased by unit conversion or rounding.
Worked Decisions
Worked Example: A Credible MABEL Candidate Is Lowest
Hypothetical case. For a potent immune-activating biologic, four analyses give comparable total-dose candidates for the same intended first exposure: NOAEL-based, 0.12 mg; HNSTD-based, 0.060 mg; MABEL-based, 0.0080 mg; and exposure-matching, 0.025 mg. Assume that the route and schedule are aligned and that the exposure analysis uses the intended human route.
The MABEL estimate is based on a relevant human-cell assay and a pharmacological response that is consistent with the proposed mechanism. The NOAEL and HNSTD analyses are also correctly calculated, but their source endpoints do not directly address the concern that even a small initial biological response could have important consequences. The exposure-matching analysis provides a separate, less restrictive constraint.
Among the applicable candidates, the minimum is:
The decision is to use 0.0080 mg as the starting-dose candidate because the MABEL evidence is relevant to the principal pharmacological concern and is credible, not simply because it is the smallest value. The other analyses do not negate that concern. The conclusion is a rationale for choosing this dose for consideration; it does not establish that a biological response or adverse effect cannot occur at 0.0080 mg.
Worked Example: The Smallest Estimate Is Not Applicable
Hypothetical case. For a small-molecule candidate, the calculated total-dose candidates are NOAEL-based, 0.040 mg; HNSTD-based, 0.030 mg; MABEL-based, 0.0050 mg; and exposure-matching, 0.012 mg. All are on the same route and schedule. The MABEL number comes from a potency assay using a species-specific target form. A follow-up assay shows that the measured response does not translate to the human target, and the candidate dose was derived by extrapolating that response as if the targets were equivalent.
The arithmetic minimum of all four numbers is:
However, this calculation does not establish a meaningful constraint: the MABEL estimate depends on a species-to-human pharmacology assumption contradicted by the evidence. Excluding that candidate requires a scientific explanation; it does not justify ignoring a low result merely because it is inconvenient. The NOAEL, HNSTD, and exposure-matching candidates remain applicable under the stated assumptions, so their minimum is:
The selected candidate is therefore 0.012 mg, constrained by exposure matching. This does not mean the excluded MABEL method is generally unimportant; it means this particular MABEL estimate is not supported as a human-relevant constraint. If the target relevance or the assay interpretation were unresolved rather than contradicted, the uncertainty would need to be addressed before relying on this exclusion.
Worked Example: Exposure Evidence Adds a Binding Constraint
Hypothetical case. Four analyses for the same intended first exposure yield total-dose candidates: NOAEL-based, 0.050 mg; HNSTD-based, 0.070 mg; MABEL-based, 0.024 mg; and exposure matching, 0.016 mg. The exposure analysis evaluates both \(C_{\max}\) and AUC. Under the stated pharmacokinetic assumptions, 0.016 mg is the lower dose that satisfies the prespecified \(C_{\max}\) constraint; the AUC-based candidate is 0.030 mg. Assume the \(C_{\max}\) constraint is relevant to the potential acute effect and the exposure prediction is supported by suitable data.
The exposure-matching candidate is not a duplicate of the MABEL estimate: it addresses a different risk through a different measure. The binding exposure candidate is 0.016 mg because it is lower than the AUC-based candidate and the acute \(C_{\max}\) concern is relevant. Comparing the applicable constraints gives:
Thus, 0.016 mg is selected as the starting-dose candidate. A dose of 0.020 mg would exceed the \(C_{\max}\)-based candidate, even though it would be below the NOAEL-, HNSTD-, and MABEL-based candidates. The result depends on the stated relevance and credibility of the \(C_{\max}\) constraint; if those assumptions changed, the exposure candidate would need reassessment rather than automatic deference.
Why the Minimum-Constraint Rule Follows
Suppose a set of \(k\) applicable methods provides upper constraints \(D_1,D_2,\ldots,D_k\) on a common dose scale. A dose \(D\) satisfies all of them only if \(D\leq D_i\) for every \(i\). In particular, it must be no greater than the smallest constraint. Conversely, any nonnegative dose no greater than that smallest value satisfies each constraint:
This establishes the arithmetic rule when the inputs truly are comparable constraints. It does not establish that every calculated candidate deserves inclusion, that the input methods capture every risk, or that the minimum itself guarantees safety. Those are scientific judgments requiring attention to the evidence, not consequences of the inequality.
Diagnostics, Alternatives, and Limitations
A disagreement should trigger checks rather than averaging. Look for mismatched units or dose bases, an incorrect route or schedule, inconsistent exposure metrics, an unsupported species translation, a safety factor applied to the wrong quantity, or a candidate that relies on a study endpoint unrelated to the main risk. Also ask whether the result changes materially under plausible assumptions. A candidate that is highly sensitive to one uncertain input may deserve less weight or may call for a more protective decision; sensitivity alone does not determine which.
The main alternative to a minimum-constraint approach is a weighted synthesis that assigns different influence to different methods. Such an approach may be useful when candidates are estimates of a common quantity and the weighting can be defended. But NOAEL, HNSTD, MABEL, and exposure-based candidates often represent different endpoints rather than repeated measurements of the same quantity. Averaging them can produce a dose that violates the most relevant constraint and has no clear interpretation. A lower dose chosen by expert judgment can also be reasonable, but the reason should connect to evidence, uncertainty, or practical dose selection rather than to an unexplained preference for a smaller number.
No selection rule removes uncertainty in translation from nonclinical evidence to a human response. A starting dose is a decision under uncertainty, and the appropriateness of its rationale depends on the quality and relevance of the supporting evidence. The purpose of comparing candidates is to make the decision traceable and internally consistent, not to turn heterogeneous evidence into a false impression of precision.
Common Pitfall
Correction: The smallest number is binding only if its method, inputs, and translation are relevant and credible for the decision. First verify comparability and applicability. If the estimate is excluded, state the evidence-based reason; if it is retained, respect it as a constraint. A numerical minimum is a decision aid, not a safety guarantee.
Check Your Understanding
Answer each question, then compare your reasoning with the solutions below.
- Three applicable and comparable candidates are 0.030 mg, 0.018 mg, and 0.025 mg. What is the largest dose satisfying all three constraints?
- Why is it generally inappropriate to average a NOAEL-based candidate and a MABEL-based candidate?
- A candidate is the smallest of four, but it depends on a species-specific pharmacology assumption contradicted by human-target data. What should be checked before using it as the binding constraint?
- Two exposure-matching candidates differ because one controls \(C_{\max}\) and the other AUC. What information is needed to decide how they constrain the starting dose?
Solutions. (1) The minimum is \(\min(0.030,0.018,0.025)=0.018\) mg, so a dose no greater than 0.018 mg satisfies all three. (2) The methods may address different endpoints and risks, so their arithmetic mean may not satisfy the most relevant constraint and has no clear common interpretation. (3) Check whether the method and its inputs are applicable to humans; if the assumption is contradicted, explain whether the candidate should be excluded, and reassess the remaining credible constraints. (4) Establish which exposure measure is relevant to the potential risk, verify the exposure predictions and assumptions, and retain each applicable constraint rather than treating the two candidates as interchangeable.